SURMOUNT-1 follow-up: diabetes progression over three years
A longer analysis focused on participants who had both obesity and prediabetes.
Published research. Clear context.
Explore what a study found—and what it cannot tell us.
These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.
Selected papers, newest publication year first.
A reading archive, not a complete systematic review.
30 study notes
Each note links to its original source.A longer analysis focused on participants who had both obesity and prediabetes.
The population and comparison define what this combination trial can tell us.
A phase 3 study extended the evidence in Chinese adults with overweight or obesity.
A kidney-outcome trial illustrates the importance of eligibility criteria and composite endpoints.
A randomized withdrawal design examined maintenance after an initial treatment period.
Two trials examined sleep-apnea measurements in adults with obesity.
SELECT studied cardiovascular events, rather than weight change alone.
This study focused on symptoms, physical limitations and body weight in a defined heart-failure population.
Who entered the randomized phase is central to interpreting this study.
A triple-receptor approach was evaluated in an early controlled obesity study.
This phase 2 study examined glycemic control alongside body weight.
A regional phase 2 study examined a dual GLP-1 and glucagon receptor approach.
Negative primary results are an important part of an evidence library.
A large randomized trial examined tirzepatide in adults with obesity or overweight without diabetes.
Longer follow-up examines maintenance during ongoing treatment, rather than permanence after stopping.
The extension study highlights why an end-of-treatment result is not a permanent-outcome guarantee.
A placebo-controlled obesity trial provides a starting point for reading the semaglutide evidence.
Intensive behavioral support is part of the context when interpreting this weight-management study.
Animal intervention experiments and measurements after human exercise answer different questions.
A head-to-head comparison needs its trial population, comparator and endpoint kept in view.
A phase 2 study investigated weight change and tolerability for an amylin analogue.
Early combination studies prioritize safety and exposure before definitive efficacy questions.
Blood metabolite patterns offer clues about mechanisms in a diet-induced obesity model.
A liver-fat endpoint was examined in a narrowly defined clinical population.
A small early study illustrates the difference between promising signals and confirmed outcomes.
Brain imaging can investigate a pathway without proving a clinical treatment effect.
An early mechanistic paper links a mitochondrial-encoded peptide to metabolic signaling.
A preliminary trial measured two different fat compartments in adults with HIV.
An early fertility study examined kisspeptin-54 within a specialist clinical protocol.
Tendon-cell experiments explore mechanisms rather than patient recovery.
Try a broader term or reset the filters.
Notes are based on the linked original paper abstracts and bibliographic records, with editorial limitations made explicit. Paper years refer to the cited journal record, which may differ from first online publication. Selection is illustrative, not exhaustive, and is not a ranking of compounds.
Clinical trials examine defined participants and interventions. Follow-up studies examine later outcomes. Preclinical studies use cells, tissues or animals. Mixed evidence combines different designs; human observations do not turn animal intervention results into clinical proof. Read the full source, methods, funding and disclosures before drawing conclusions.
Collection prepared October 18, 2026. This page does not track every subsequent publication or regulatory change.